Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY293111 · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Gemcitabine | DRUG | - |
| LY293111 | DRUG | - |
| cisplatin | DRUG | - |
| placebo | DRUG | - |
Inclusion Criteria: * Non-Small Cell Lung Cancer, Stage IIIB or IV that is not amenable to either surgery of curative intent or radiation therapy * Tumor that can be measured by x-ray or scan * Adequate organ function Exclusion Criteria: * Inability to swallow capsules * Documented brain metastas...
LY293111 is an investigational small molecule being studied for the treatment of pancreatic cancer and non-small-cell lung cancer. It was evaluated in Phase 2 clinical trials in combination with other agents for these oncology indications.
LY293111 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol LLY.
LY293111 is in Phase 2 clinical development. It has completed two Phase 2 trials, one in pancreatic cancer and one in non-small-cell lung cancer, and is not approved for any use.
LY293111 has been studied in two completed Phase 2 trials: NCT00055250, which tested LY293111 with gemcitabine and placebo in patients with pancreatic cancer, and NCT00069875, which tested LY293111 with gemcitabine and cisplatin in non-small-cell lung cancer.
LY293111 is also known by the code name LY293111. No other alternative names have been disclosed for this investigational agent.